Merck, GE to collaborate on Alzheimer's drug development

Tue Dec 18, 2012 10:51pm IST

A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009. REUTERS/Jeff Zelevansky

A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009.

Credit: Reuters/Jeff Zelevansky

Related Topics



(Reuters) - Merck & Co and General Electric Co's healthcare unit have agreed to collaborate on an experimental drug for Alzheimer's disease, the companies said on Tuesday.

GE Healthcare will supply Flutemetamol, an investigational imaging agent, to Merck for use with its experimental Alzheimer's disease drug MK-8931.

The companies hope GE's imaging agent will help identify patients who might benefit from a therapy such as Merck's, which targets beta amyloid, a protein that can clump together and form plaques in the brain. Such plaques have been found in the brains of patients with Alzheimer's disease.

MK-8931 is Merck's lead Alzheimer's drug candidate and is designed to modify progression of the disease as well as improve symptoms. Alzheimer's robs patients of their memory and can cause other cognitive disturbances.

Based on promising results from an early-stage clinical trial of MK-8931, Merck plans to move forward with a larger trial, called EPOCH, at multiple sites around the world.

Flutemetamol is a positron emission tomography (PET) imaging agent that has been able, in clinical trials, to detect beta amyloid in the brain.

GE Healthcare will supply Flutemetamol to help select patients for clinical trials and evaluate the agent as a companion diagnostic tool. Financial and other terms of the agreement between the companies were not disclosed.

(Reporting By Toni Clarke; editing by John Wallace)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Disease Outbreak


Reading the Brain

Reading the Brain

Guilt may spoil restorative effects of entertainment.  Full Article 

Heart Matters

Heart Matters

Weekday heart attacks still getting quicker treatment at hospitals.  Full Article 

Tackling Stress

Tackling Stress

'Interreality' may enhance stress therapies.  Full Article 

Jogging Helps

Jogging Helps

Short jogs linked to lower risk of death from heart disease.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage